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a Given Patient
Drug-Coated Stents for the Treatment of Coronary Disease*Marie-Claude Morice, MD, Fadi J. Sawaya, MDS ince the initial case of plain old balloon angio-plasty by Andreas Grüntzig in 1977, there hasbeen tremendous advancement in the treat-
ment of coronary artery disease. After balloons and
bare-metal stents (BMS), the introduction of drug-
eluting stents (DES) in 2002 transformed the practice
of percutaneous coronary intervention (PCI) by
signiﬁcantly reducing rates of restenosis and repeat
revascularization caused by the excessive tissue pro-
liferation seen after BMS (1). The safety concerns
raised by the ﬁrst-generation sirolimus- and
paclitaxel-eluting stents (PES) in regard to higher rates
of late stent thrombosis (ST) and very late ST prom-
pted changes to DES (2). The second-generation DES
employed new stent designswith thinner struts, stron-
ger materials such as cobalt or platinum-chromium
with more biocompatible permanent polymers, and
new antiproliferative drugs such as everolimus and
zotarolimus, which further improved performance
with lower rates of restenosis and late ST but still
required long-term dual antiplatelet therapy (DAPT)
(3). Other DES with bioresorbable polymers were
also developed and signiﬁcantly decreased the late
ST phenomenon (4).SEE PAGE 51In this issue of JACC: Cardiovascular Interventions,
Costa et al. (5) report on a novel nonpolymeric drug-
coated stent (DCS) that is now being introduced as
an alternative to polymeric DES. This stent was*Editorials published in JACC: Cardiovascular Interventions reﬂect the
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relevant to the contents of this paper to disclose.designed to possibly accelerate healing and abolish
the potential adverse effects of polymers. Polymers
are susceptible to cracking and shearing, which affects
the integrity of the stent surface and can poten-
tially generate long-term inﬂammation, delayed
endothelialization, hypersensitivity reactions, neo-
atherosclerosis, and late acquired incomplete stent
apposition (6).
The BioFreedom DCS (Biosensors Europe S.A.
Corporation, Morges, Switzerland) transfers Biolimus
A9, a highly lipophilic sirolimus analogue, into the
vessel wall. As described by Costa et al. (5), the DCS is
composed of 3 key components, including a 316L
stainless steel platform that has been reformed with a
proprietary surface treatment, resulting in a selec-
tively microstructured, abluminal surface. This al-
lows Biolimus A9 to adhere to the stent surface and be
delivered to the vessel wall over a relatively short
time course, with 98% of the drug being released
within 28 days (7,8). Overall, this novel stent has been
designed to allow normal healing of the artery with
the intent of reducing restenosis compared with BMS
and to potentially obviate the need for long term
DAPT compared with DES.
In a well-designed prospective, randomized, single-
blind multicenter feasibility study, Costa et al. (5)
compared the performance, safety, and efﬁcacy of a
novel standard-dose BioFreedom drug-coated stent
(BFD) and low-dose BioFreedom drug-coated stent
(BFD-LD) with the Taxus Liberté PES (Boston Scienti-
ﬁc, Marlborough, Massachusetts) in the treatment of
de novo coronary artery disease in 182 patients. Their
primary endpoint was in-stent late lumen loss (LLL) at
12 months as determined by quantitative coronary
angiography.
The investigators had several important ﬁndings.
The study met the primary outcomes of terms of
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66noninferiority at 12 months (e.g., in-stent LLL at
12 months: 0.17 mm in the BFD group compared with
0.35 mm in the PES group; p < 0.001) with a trend
toward superiority (p ¼ 0.11). Conversely, the BFD-LD
did not reach noninferiority compared with PES.
Although the study was not powered for clinical
outcomes, there were no signiﬁcant differences be-
tween the 3 groups in major adverse cardiac events up
to 5 years (23.8%, 26.4%, and 20.4% for BFD, BFD-LD,
and PES, respectively), and there was an absence of
deﬁnite or probable ST in all groups (minimum dura-
tion of DAPTwas 6months). Clinically indicated target
lesion revascularization (TLR) was also not different
between the 3 groups at 5 years (10.8%, 13.4%, and
10.2% for BFD, BFD-LD, and PES, respectively).
In general, 2 main features should be considered
when assessing the results of a new active stent—
efﬁcacy and safety. The new stent should be non-
inferior or equivalent in terms of TLR compared with
a market leader or “gold standard” DES. It should also
display similar, if not superior, safety results
compared with BMS and current DES. Generally, 12-
month results are required to support early safety
and efﬁcacy, and longer follow-up, up to 5 years, is
important to address the concerns of very late ST and
catch-up restenosis.
In terms of efﬁcacy, the BFD was compared with a
ﬁrst-generation PES that was an appropriate control
at the time of study enrollment, and did indeed show
a nonsigniﬁcant reduction in median in-stent LLL
from 0.35 to 0.17 mm at 12 months. However, this
comparison is now somewhat dated, because several
randomized trials (SPIRIT [Clinical Evaluation of the
XIENCE V Everolimus Eluting Coronary Stent System
in the Treatment of Patients With De Novo Native
Coronary Artery Lesions) III, SPIRIT IV, and TUXEDO
[The Taxus Element versus Xience Prime in a Diabetic
Population]) have demonstrated that the use of per-
manent polymer EES resulted in consistent reduced
angiographic LLL, noninferior rates of target vessel
failure, and fewer major adverse cardiac events than
PES at 1 year and up to 5 years of follow-up (9–11).
Nonetheless, numerically the in-stent LLL of 0.17
mm seen with BFD was not very different from the in-
stent LLL of 0.14 mm seen in the SPIRIT III trial at 8
months (9). This observation also applies to the rate
of TLR at 5 years that was 10.8% in the BFD group
versus 8.9% in the Xience V (Abbott Vascular, Santa
Clara, California) group studied in the SPIRIT III trial
(10). Although no real comparison can be made
without a randomized study directly comparing the 2
stents, the outcomes of the BFD in this study give
reason for initial optimism on the potential effec-
tiveness and safety of the stent.One of the initial concerns that the study in-
vestigators had regarding the stent was the fear
that rapid drug elution would affect stent efﬁcacy,
as shown with earlier polymer-free stents such as
the Yukon stent, which was associated with an in-
stent LLL of 0.48 mm (i.e., higher than a PES
comparator) (12,13). Importantly, this fear was un-
founded. Costa et al. (5) suggest that Biolimus
A9 may have optimal pharmacokinetics due to its
high lipophilic nature, allowing for a fast but
extended treatment effect while counteracting the
boost effect (8).
As far as safety of the stent, although no cases of ST
occurred, the study was not powered for such rare
events.
As noted by Costa et al. (5), the population studied
was small and only included a sample of simple,
short, and discrete type A lesions with an average of
1 stent/patient. Due to the trends of both the clinical
efﬁcacy and safety of the stent in this study, the
authors proposed that a potential use for the
polymer-free stent, due to its rapid drug elution,
would be for patients who require a DES but are un-
able to receive prolonged DAPT. This potential was
studied and recently published in the landmark
LEADERS FREE double-blind trial, which compared
the safety and efﬁcacy of the biolimus-eluting DCS
with the Gazelle BMS (Biosensors International,
Singapore) in patients at high risk for bleeding post-
PCI (14). A total of 2,432 patients were enrolled and
treated with 1-month DAPT only followed by single
antiplatelet treatment. The results clearly showed
superior safety at 1 year with the DCS versus BMS
with regard to cardiac death, MI, and ST (9.4% vs.
12.9%; p for superiority ¼ 0.005). They also docu-
mented markedly lower rates of TLR (5.1% vs. 9.8%;
p < 0.0001) (14).
The ﬁeld of PCI continues to evolve with the
introduction in the last couple of years of new de-
vices, including stents with biodegradable polymers,
biodegradable scaffolds, and now, polymer-free
stents. Although clinical data have accumulated to
support the use of biodegradable polymer stents and
to a lesser extent bioresorbable scaffolds, data on
polymer-free devices were conﬂicting and limited
until now. When combining this ﬁrst-in-man study
with the results of the LEADERS FREE trial, it ap-
pears that the standard-dose biolimus DCS is non-
inferior to ﬁrst-generation DES in terms of late
lumen loss and is superior in efﬁcacy and safety
compared with BMS in patients with high bleeding
risk on 1 month of DAPT. Indeed, such patients
currently seem to represent the ideal candidates for
these polymer-free stents. Whether biolimus DCS
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 1 , 2 0 1 6 Morice and Sawaya
J A N U A R Y 1 1 , 2 0 1 6 : 6 5 – 7 Drug-Coated Stents for the Treatment of Coronary Disease
67has the same safety and efﬁcacy compared with a
second-generation DES in a nonselected population
remains to be proven.
This is again an exciting time for coronary inter-
vention, as the quest for the ideal personalized cor-
onary stent seems to become a reality.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
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